US FDA staff question Chiron lung transplant drug

WASHINGTON (Reuters) - A small, limited clinical trial for Chiron Corp.'s experimental lung transplant drug Pulminiq does not show the treatment makes a difference, U.S. Food and Drug Administration staff reviewers said in documents released on Friday.

Continue to US FDA staff question Chiron lung transplant drug on Reuters: Health.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz